-

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contacts

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Industry:

Alkermes plc

NASDAQ:ALKS
Release Versions
English

Contacts

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

More News From Alkermes plc

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH). The Brilliance Studies program consists of three 12-...

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or community health center settings and who possess a commitment to a...

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in th...
Back to Newsroom